Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

CS. Fuchs, S. Azevedo, T. Okusaka, JL. Van Laethem, LR. Lipton, H. Riess, C. Szczylik, MJ. Moore, M. Peeters, G. Bodoky, M. Ikeda, B. Melichar, R. Nemecek, S. Ohkawa, A. Świeboda-Sadlej, SA. Tjulandin, E. Van Cutsem, R. Loberg, V. Haddad, JL....

. 2015 ; 26 (5) : 921-7. [pub] 20150121

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020993

BACKGROUND: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m(2) (days 1, 8, and 15 of each 28-day cycle) plus placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/kg (days 1 and 15 of each cycle). The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), safety, and efficacy by levels of circulating biomarkers. RESULTS: Overall, 322 patients were randomly assigned to placebo, 318 to ganitumab 12 mg/kg, and 160 to ganitumab 20 mg/kg. The study was stopped based on results from a preplanned futility analysis; the final results are reported. Median OS was 7.2 months [95% confidence interval (CI), 6.3-8.2] in the placebo arm, 7.0 months (95% CI, 6.2-8.5) in the ganitumab 12-mg/kg arm [hazard ratio (HR), 1.00; 95% CI, 0.82-1.21; P = 0.494], and 7.1 months (95% CI, 6.4-8.5) in the ganitumab 20-mg/kg arm (HR, 0.97; 95% CI, 0.76-1.23; P = 0.397). Median PFS was 3.7, 3.6 (HR, 1.00; 95% CI, 0.84-1.20; P = 0.520), and 3.7 months (HR, 0.97; 95% CI, 0.77-1.22; P = 0.403), respectively. No unexpected toxicity was observed with ganitumab plus gemcitabine. The circulating biomarkers assessed [insulin-like growth factor-1 (IGF-1), IGF-binding protein-2, and -3] were not associated with a treatment effect on OS or PFS by ganitumab. CONCLUSION: Ganitumab combined with gemcitabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01231347.

Department of Clinical Pharmacology and Chemotherapy Russian Cancer Research Center Moscow Russia

Department of Gastroenterology Erasme University Hospital Brussels Belgium

Department of Gastroenterology Kanagawa Cancer Center Yokohama Japan

Department of Haematology Oncology and Internal Medicine Medical University of Warsaw Warsaw Poland

Department of Hematology Oncology and Tumor Immunology Charité University Berlin Germany

Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Kashiwa Japan

Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan

Department of Medical Oncology Solid Tumor Oncology Dana Farber Cancer Institute Boston USA

Department of Oncology Antwerp University Hospital Edegum Belgium

Department of Oncology Masaryk University Medical School and Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology Military Institute of Health Services Warsaw Poland

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc

Department of Oncology St László Hospital Budapest Hungary

Development Oncology Therapeutics Amgen Inc Thousand Oaks USA

Digestive Oncology University Hospitals Gasthuisberg Leuven and KU Leuven Leuven Belgium

Global Biostatistical Science Amgen Ltd Cambridge UK

Global Development Thousand Oaks

Medical Oncology Department University Hospital Ramon y Cajal Madrid Spain

Medical Oncology Royal Melbourne Hospital Parkville VIC Australia

Medical Sciences Amgen Inc Thousand Oaks USA

Oncology Service Hospital de Clinicas de Porto Alegre Porto Alegre Brazil

Princess Margaret Cancer Centre University of Toronto Toronto ON Canada

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020993
003      
CZ-PrNML
005      
20180503151233.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdv027 $2 doi
024    7_
$a 10.1093/annonc/mdv027 $2 doi
035    __
$a (PubMed)25609246
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fuchs, C S $u Department of Medical Oncology/Solid Tumor Oncology, Dana-Farber Cancer Institute, Boston, USA charles_fuchs@dfci.harvard.edu.
245    12
$a A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial / $c CS. Fuchs, S. Azevedo, T. Okusaka, JL. Van Laethem, LR. Lipton, H. Riess, C. Szczylik, MJ. Moore, M. Peeters, G. Bodoky, M. Ikeda, B. Melichar, R. Nemecek, S. Ohkawa, A. Świeboda-Sadlej, SA. Tjulandin, E. Van Cutsem, R. Loberg, V. Haddad, JL. Gansert, BA. Bach, A. Carrato,
520    9_
$a BACKGROUND: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m(2) (days 1, 8, and 15 of each 28-day cycle) plus placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/kg (days 1 and 15 of each cycle). The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), safety, and efficacy by levels of circulating biomarkers. RESULTS: Overall, 322 patients were randomly assigned to placebo, 318 to ganitumab 12 mg/kg, and 160 to ganitumab 20 mg/kg. The study was stopped based on results from a preplanned futility analysis; the final results are reported. Median OS was 7.2 months [95% confidence interval (CI), 6.3-8.2] in the placebo arm, 7.0 months (95% CI, 6.2-8.5) in the ganitumab 12-mg/kg arm [hazard ratio (HR), 1.00; 95% CI, 0.82-1.21; P = 0.494], and 7.1 months (95% CI, 6.4-8.5) in the ganitumab 20-mg/kg arm (HR, 0.97; 95% CI, 0.76-1.23; P = 0.397). Median PFS was 3.7, 3.6 (HR, 1.00; 95% CI, 0.84-1.20; P = 0.520), and 3.7 months (HR, 0.97; 95% CI, 0.77-1.22; P = 0.403), respectively. No unexpected toxicity was observed with ganitumab plus gemcitabine. The circulating biomarkers assessed [insulin-like growth factor-1 (IGF-1), IGF-binding protein-2, and -3] were not associated with a treatment effect on OS or PFS by ganitumab. CONCLUSION: Ganitumab combined with gemcitabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01231347.
650    _2
$a adenokarcinom $x krev $x farmakoterapie $x mortalita $x sekundární $7 D000230
650    _2
$a intravenózní podání $7 D061605
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a protinádorové antimetabolity $x aplikace a dávkování $x škodlivé účinky $7 D000964
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a deoxycytidin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D003841
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory slinivky břišní $x krev $x farmakoterapie $x mortalita $x patologie $7 D010190
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Azevedo, S $u Oncology Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. $7 gn_A_00010693
700    1_
$a Okusaka, T $u Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
700    1_
$a Van Laethem, J-L $u Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium.
700    1_
$a Lipton, L R $u Medical Oncology, Royal Melbourne Hospital, Parkville, VIC, Australia.
700    1_
$a Riess, Hanno, $d 1950- $7 xx0223974 $u Department of Hematology, Oncology, and Tumor Immunology, Charité University, Berlin, Germany.
700    1_
$a Szczylik, C $u Department of Oncology, Military Institute of Health Services, Warsaw, Poland.
700    1_
$a Moore, M J $u Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
700    1_
$a Peeters, M $u Department of Oncology, Antwerp University Hospital, Edegum, Belgium.
700    1_
$a Bodoky, G $u Department of Oncology, St László Hospital, Budapest, Hungary.
700    1_
$a Ikeda, M $u Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
700    1_
$a Melichar, B $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc.
700    1_
$a Nemecek, R $u Department of Oncology, Masaryk University Medical School and Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Ohkawa, S $u Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
700    1_
$a Świeboda-Sadlej, A $u Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Tjulandin, S A $u Department of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow, Russia.
700    1_
$a Van Cutsem, E $u Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium.
700    1_
$a Loberg, R $u Medical Sciences, Amgen Inc., Thousand Oaks, USA.
700    1_
$a Haddad, V $u Global Biostatistical Science, Amgen Ltd, Cambridge, UK.
700    1_
$a Gansert, J L $u Global Development, Thousand Oaks.
700    1_
$a Bach, B A $u Development Oncology Therapeutics, Amgen Inc., Thousand Oaks, USA.
700    1_
$a Carrato, A $u Medical Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology ESMO $x 1569-8041 $g Roč. 26, č. 5 (2015), s. 921-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25609246 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20180503151353 $b ABA008
999    __
$a ok $b bmc $g 1155663 $s 945521
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 26 $c 5 $d 921-7 $e 20150121 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options